Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia.

When I started my career in leukemia research, interferon alfa was standard therapy for patients with chronic myeloid leukemia (CML). Interferon could induce complete cytogenetic response (CCyR; ie, 0% Philadelphia-chromosome metaphases) or partial cytogenetic response (PCyR; ie, 1% to 35%), and such responses were associated with improved survival. These… CONTINUE READING